InflaRx (IFRX) Cash from Investing Activities Growth (5y) (2021 - 2026)
InflaRx (IFRX) Cash from Investing Activities Growth (5y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 50.33% |
| Dec 31, 2025 | 24.41% |
| Sep 30, 2025 | -21.85% |
| Jun 30, 2025 | -25.50% |
| Mar 31, 2025 | 52.30% |
| Dec 31, 2024 | -39.44% |
| Sep 30, 2024 | 23.41% |
| Jun 30, 2024 | -19.88% |
| Mar 31, 2024 | 151.37% |
| Dec 31, 2023 | -14.88% |
| Sep 30, 2023 | 15.68% |
| Jun 30, 2023 | -21.44% |
| Mar 31, 2023 | -89.27% |
| Dec 31, 2022 | 94.26% |
| Sep 30, 2022 | 145.68% |
| Jun 30, 2022 | -237.20% |
| Mar 31, 2022 | 303.90% |
| Dec 31, 2021 | -280.03% |